Ubs Group Ag Synaptogenix, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.16 - $0.3 $708 - $1,327	4,425 Added 245.83%	6,225 $1,000
Q4 2023 Feb 09, 2024	BUY	$0.23 - $0.4 $414 - $720	1,800 New	1,800 $0
Q1 2023 May 12, 2023	BUY	$0.8 - $1.33 $6,416 - $10,666	8,020 Added 996.27%	8,825 $7,000
Q4 2022 Feb 08, 2023	BUY	$1.02 - $181.75 $530 - $94,510	520 Added 182.46%	805 $0
Q3 2022 Nov 10, 2022	SELL	$4.6 - $172.25 $7,962 - $298,164	-1,731 Reduced 85.86%	285 $2,000
Q2 2022 Aug 10, 2022	BUY	$3.88 - $7.41 $69 - $133	18 Added 0.9%	2,016 $10,000
Q1 2022 May 16, 2022	BUY	$6.31 - $10.09 $12,607 - $20,159	1,998 New	1,998 $15,000
Q3 2021 Nov 15, 2021	SELL	$6.65 - $12.1 $21,512 - $39,143	-3,235 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$5.12 - $11.13 $16,563 - $36,005	3,235 New	3,235 $32,000

30K

Ticker SNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,840,630
Market Cap $21M
Description
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.